Literature DB >> 26607136

Role of exosite binding modulators in the inhibition of Fxa by TFPI.

Sameera Peraramelli, Stella Thomassen1, Alexandra Heinzmann, Tilman M Hackeng, Rudolf Hartmann, Friedrich Scheiflinger, Michael Dockal, Jan Rosing.   

Abstract

Tissue factor pathway inhibitor (TFPI) down-regulates the extrinsic coagulation pathway by inhibiting FXa and FVIIa. Both TFPI and FXa interact with several plasma proteins (e. g. prothrombin, FV/FVa, protein S) and non-proteinaceous compounds (e. g. phospholipids, heparin). It was our aim to investigate effects of ligands that bind to FXa and TFPI on FXa inhibition by full-length TFPI (designated TFPI) and truncated TFPI (TFPI1-150). Inhibition of FXa by TFPI and TFPI1-150 and effects of phospholipids, heparin, prothrombin, FV, FVa, and protein S thereon was quantified from progress curves of conversion of the FXa-specific chromogenic substrate CS11-(65). Low concentrations negatively charged phospholipids (~10 µM) already maximally stimulated (up to 5- to 6-fold) FXa inhibition by TFPI. Unfractionated heparin at concentrations (0.2-1 U/ml) enhanced FXa inhibition by TFPI ~8-fold, but impaired inhibition at concentrations > 1 U/ml. Physiological protein S and FV concentrations both enhanced FXa inhibition by TFPI 2- to 3-fold. In contrast, thrombin-activated FV (FVa) impaired the ability of TFPI to inhibit FXa. FXa inhibition by TFPI1-150 was not affected by FV, FVa, protein S, phospholipids and heparin. TFPI potently inhibited FXa-catalysed prothrombin activation in the absence of FVa, but hardly inhibited prothrombin activation in the presence of thrombin-activated FVa. In conclusion, physiological concentrations TFPI (0.25-0.5 nM TFPI) inhibit FXa with a t1/2 between 3-15 minutes. Direct FXa inhibition by TFPI is modulated by physiological concentrations prothrombin, FV, FVa, protein S, phospholipids and heparin indicating the importance of these modulators for the in vivo anticoagulant activity of TFPI.

Entities:  

Keywords:  Exosites; TFPI; factor V/Va; factor Xa; prothrombin

Mesh:

Substances:

Year:  2015        PMID: 26607136     DOI: 10.1160/TH15-04-0354

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Measurement of plasma and platelet tissue factor pathway inhibitor, factor V and Protein S in people with haemophilia.

Authors:  Paul E R Ellery; Ida Hilden; Peter Thyregod; Nicholas D Martinez; Susan A Maroney; Joan C Gill; Alan E Mast
Journal:  Haemophilia       Date:  2019-10-14       Impact factor: 4.287

2.  Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation.

Authors:  Salvatore Santamaria; Natalia Reglińska-Matveyev; Magdalena Gierula; Rodney M Camire; James T B Crawley; David A Lane; Josefin Ahnström
Journal:  J Biol Chem       Date:  2017-04-18       Impact factor: 5.157

3.  MASP-2 Is a Heparin-Binding Protease; Identification of Blocking Oligosaccharides.

Authors:  Ditmer T Talsma; Felix Poppelaars; Wendy Dam; Anita H Meter-Arkema; Romain R Vivès; Peter Gál; Geert-Jan Boons; Pradeep Chopra; Annamaria Naggi; Marc A Seelen; Stephan P Berger; Mohamed R Daha; Coen A Stegeman; Jacob van den Born
Journal:  Front Immunol       Date:  2020-04-28       Impact factor: 7.561

4.  Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation.

Authors:  M Ibrahim-Kosta; P Suchon; F Couturaud; D Smadja; R Olaso; M Germain; N Saut; L Goumidi; C Derbois; F Thibord; S Debette; P Amouyel; J F Deleuze; P van Doorn; E Castoldi; E Patin; M C Alessi; D A Trégouët; P E Morange
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

5.  A hydrophobic patch (PLVIVG; 1481-1486) in the B-domain of factor V-short is crucial for its synergistic TFPIα-cofactor activity with protein S and for the formation of the FXa-inhibitory complex comprising FV-short, TFPIα, and protein S.

Authors:  Björn Dahlbäck; Sinh Tran
Journal:  J Thromb Haemost       Date:  2022-03-16       Impact factor: 16.036

6.  A clinically relevant and bias-controlled murine model to study acute traumatic coagulopathy.

Authors:  C Gangloff; O Grimault; M Theron; K Pichavant; H Galinat; F Mingant; Y Ozier
Journal:  Sci Rep       Date:  2018-04-10       Impact factor: 4.379

7.  Factor V-short and protein S as synergistic tissue factor pathway inhibitor (TFPIα) cofactors.

Authors:  Björn Dahlbäck; Li Jun Guo; Ruzica Livaja-Koshiar; Sinh Tran
Journal:  Res Pract Thromb Haemost       Date:  2017-12-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.